BioLineRx

BioLineRx plans phase III BL-8040 registrational study of stem cell mobilization

Tuesday, August 22, 2017

BioLineRx, a clinical-stage biopharmaceutical company focused on oncology and immunology, announced the filing of regulatory submissions required to commence a randomized, controlled phase III registrational trial of BL-8040 for the mobilization of hematopoietic stem cells for autologous transplantation in patients with multiple myeloma. The trial, named GENESIS, is expected to commence by the end of 2017, following receipt of regulatory approvals.

[Read More]

BioLineRx acquires Agalimmune to accelerate immuno-oncology pipeline

Thursday, March 23, 2017

BioLineRx, a clinical-stage biopharmaceutical company focused on oncology and immunology, has acquired Agalimmune, a private U.K.-based company with an innovative, anti-cancer immunotherapy platform. Acquisition consideration consisted of a $6 million upfront payment, of which $3 million is in cash and the remainder in BioLineRx shares. Additional future payments may be made based on development and commercial milestones.

[Read More]

BioLineRx, I-Bridge Capital establish China joint venture

Friday, August 26, 2016

BioLineRx, a clinical stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, has established a joint venture (JV) with I-Bridge Capital, a Chinese venture capital fund focused on developing innovative therapies in China. The joint venture, named iPharma, will develop innovative clinical and preclinical therapeutic candidates originating primarily in Israel to serve the Chinese and global healthcare markets. 

[Read More]

BioLineRx receives Orphan Drug designation for stem cell mobilization treatment

Friday, January 24, 2014

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, has received notice from the FDA confirming an Orphan Drug Designation of BL-8040 as a treatment for stem cell mobilization, in addition to the Orphan Drug Designation previously granted to BL-8040 as a treatment for Acute Myeloid Leukemia (AML).

[Read More]